Clinical Trials
Currently Recruiting
-
GSK208750
Long-Term Follow-Up (LTFU) of Participants Treated with GSK Adoptive Cell Therapies
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT03391778
-
SQZ-PBMC-HPV-101
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Principal Investigator: Dr. Neesha Dhani
NCT#: NCT04084951
-
CRSP-ONC-003
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT04438083
-
TCR2-18-01
A Phase 1/2 Single Arm Open-Label Clinical Trial of Tc-210 T Cells In Patients with Advanced Mesothelin-Expressing Cancer
Principal Investigator: Dr. Marcus Butler
NCT#: NCT03907852
-
IOV-LUN-202
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT04614103
-
TAC01-HER2-03
A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)
Principal Investigator: Dr. Adrian Sacher
NCT#: NCT04727151
Closed Recruiting
-
1301-02
Phase 1b Study of NY-ESO-1 specific TCR gene transduced autologous T lymphocytes in patients with solid tumors
Sponsor: In-house (in collaboration with Takara Bio Inc)
Principal Investigator: Marcus Butler
NCT#: NCT02869217
-
TILs-003-Meso
Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)
Sponsor: In-House
Principal Investigator: Dr. Marcus Butler
NCT#: NCT02414945
https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1
-
INSPIRE
INvestigator-initiated Phase II Study of pembrolizumab immunological response evaluation
Sponsor: In-House
Principal Investigator: Dr. Lillian Siu
NCT#: NCT02644369
-
ACTIVATE
Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study
Sponsor: In-House
Principal Investigator: Dr. Marcus Butler
NCT#: NCT02811497